Posts Tagged ‘ statins ’

Top 10 2012 FDA Consumer Health Update Topics

February 12th, 2013. By AbiK

Ever wonder what gets the most traffic over at the FDA website? According to an update at the Brandon Patch, more than 7.3 million people visited the Food and Drug Administration online last year to check out the consumer updates section of the website (fda.gov). What were they looking for? The following were the ten most popular topics readers sought out at the FDA. Many, as you’ll see, were topics covered at LawyersandSettlements.com as well.

Top 10 2012 FDA Consumer Health Update Topics

1. When to dispose of unused medicines–how long should medicines be kept and how to safely dispose of them.

2. Questions regarding potentially harmful presence of mercury in skin products sold illegally in U.S.

3. HCG diet products and their potential link to blood clots, depression and other harmful side effects.

4. Dietary supplement Hydroxycut, and its alleged connection to liver-related illness.

5. Questions over arsenic contained in rice.

6. Concerns over tattoo inks being linked to serious infection.

7. Safety concerns over the additive triclosan, which is commonly found in antibacterial lotions or hand sanitizers.

8. Thickening agents, like SimplyThick, which were connected to reports of infant deaths.

9. Statins and the risk of rhabdomyolysis and cardiomyopathy.

10. Finally, one for man’s best friend: information on the symptoms and treatment of Cushing’s disease in dogs.

Tags: Arsenic, FDA, HCG, Hydroxycut, Mercury, SimplyThick, statins, Tattoo Ink, Triclosan
Posted in Emerging Issues, Personal Injury | 1 Comment »

Top 10 Drug Legal News Topics For 2012

December 24th, 2012. By AbiK

LawyersandSettlements.com recently shared its list of the hottest consumer-related pharmaceutical legal news stories during the last year. Of note is that while the top drug-related topic on the legal news website in 2011 had been Tylenol—prompted by concerns over a series of Tylenol recall notices as reported by The New York Times; for 2012, the most sought out pharmaceutical topics have shifted to women’s health.

Third-generation contraceptives such as Yasmin/Yaz, NuvaRing and Mirena top the list this year as numerous birth control lawsuits either settled, or began the process of consolidation into multi-district litigation (MDL).

Reader interest in Yaz/Yasmin rose in response to Yasmin lawsuit settlements that were announced in April (In re Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Product Liability Litigation, 09-md-02100, U.S. District Court, Southern District of Illinois, East St. Louis). Bloomberg reported Bayer AG settled about 500 Yasmin lawsuits over claims of blood clots that had, in some cases, led to stroke or heart attack.

Along with Yaz, readers remained concerned about NuvaRing (etonogestrel/ethinyl estradiol) and blood clot risk even as a new study on non-oral hormonal contraception, published in the British Medical Journal (BMJ 2012;344:e2990), was presented at the annual meeting of the American College of Obstetricians and Gynecologists (May, 2012). The study, aimed at quantifying NuvaRing blood clot risk, indicated no significant difference in risk of venous thromboembolism when compared to oral contraceptives.

Still, NuvaRing lawsuits continue and have been consolidated into a federal MDL court in Missouri (In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri). As of September 5, 2012, according to the U.S. Panel on Multidistrict Litigation, more than 1,000 NuvaRing lawsuits have been filed.

Mirena IUD (levonorgestrel) saw an increase in reader interest after August 2012, as Bayer Healthcare Pharmaceuticals, Inc. submitted an Application for Centralized Management of Certain Cases involving Mirena. As FoxNews reported (11/11/12), the request seeks to create a multi-district litigation (MDL) for 16 pending Mirena lawsuits in NJ that allege Mirena caused uterine perforation, infection and hemorrhaging injuries.

After the top three women’s health-related drugs, Pradaxa (dabigatran), an alternative to warfarin, joined the list this year making the Top 5. In November 2012, the FDA issued a Drug Safety Communication regarding Pradaxa bleeding events which in turn helped drive reader interest.

Thousands of LawyersandSettlements.com monthly readers have followed the latest legal news and information on these topics, many of which have fallen from the radar of traditional media outlets.

“We believe these issues are of great importance to the public, mostly due to the life-changing impact they can have on an individual,” said Stephen King, CEO. “Some of our most interesting stories of the year related to pharmaceuticals. Many of them have pending lawsuits or have had substantial settlements related to their life-altering side effects and it’s important to get this information out to the public. While many pharmaceutical companies continue to earn significant profits, people are suffering. They may think they have no recourse but in many cases they do. By keeping these topics alive, LawyersandSettlements.com is helping people stay up-to-date on these important topics every day.”

The LawyersandSettlements.com Top 10 Pharmaceutical Topics of 2012, along with the potential side effects readers were seeking information on, are:

1. Yasmin/YAZ (gall bladder disease, blood clots, deep vein thrombosis, pulmonary embolism)

2. NuvaRing & Mirena (blood clots, infection, perforation of the uterus)

3. Pradaxa (uncontrollable bleeding, lack of an available antidote)

4. Granuflo (elevated bicarbonate levels, risk for metabolic alkalosis)

5. SSRIs (birth defects including heart defects, spina bifida, cleft palate, club foot, PPHN)

6. Actos (bladder cancer, heart failure, kidney failure, rhabdomyolysis)

7. Diethylstilbestrol/DES (cancer)

8. Crestor / Statins (diabetes, cardiomyopathy, rhabdomyolysis)

9. Fosamax (bone fractures, esophageal cancer)

10. Propecia (sexual dysfunction, erectile dysfunction, sterility, prostate cancer)

LawyersandSettlements.com readers are looking for the latest and most comprehensive legal news available. Those seeking legal help can request assistance by completing a form which is then distributed to attorneys specializing in these cases. Over two and a half million people visit the site yearly, and hundreds of thousands of request forms have been submitted by qualified readers looking for legal guidance.

Tags: Actos, Birth Control Side Effects, Class Action Lawsuit, Crestor, DES, Drug Injury, Drug Lawsuit, Fosamax, Granuflo, Lawsuit, Legal News, Mirena, NuvaRing, Pradaxa, Propecia, SSRI, statins, Yasmin, Yaz
Posted in Class Action, Drugs/Medical, Emerging Issues | No Comments »

Cholesterol Drug and Cardiomyopathy – Why didn’t Anyone Tell me?

August 1st, 2011. By Hunter West

I have just been put on a statin because my cholesterol is too high. Apparently my doctor says, at 54, I am at a high risk for heart attack and stroke.

Nice. This, in spite of the fact I have no history of heart disease in my family, I have never smoked, I have exercised semi-regularly and have always watched my weight.

Okay, maybe I haven’t been watching what I eat. I like my steaks and prime rib like everybody else. Butter on popcorn, if you please. And perhaps, on occasion, a beer or two, too many.

And okay, while never an exercise demon I was always a fairly active guy. Rode my bike to work. In the late 90’s I took up walking for health, and to lose a few pounds. Then in 2002 I took up running. I ran a half-marathon in under two hours. And I trained for a full marathon (although I never completed the actual race). I got myself down to my high school weight of 129.

But for the past five years I haven’t done a lot, due to work commitments. Is that the reason for my current troubles? Can five years of inactivity cancel out 40 years of fairly active living?

I guess…

So now I’m on low-dose Aspirin once a day, to thin the blood out. And now, as of last night, I’m on a statin to reduce my bad cholesterol.

Overall, statins are considered good things. And not all statins are created equal. Thankfully, I’m not on Zocor, or Vytorin. I’m on another one. But at 10mg, I’m on the highest dose Read the rest of this entry »

Tags: Cardiomyopathy, Cholesterol, Crestor, Rhabdomyolysis, Statin drugs, statins
Posted in Drugs/Medical, Emerging Issues | 6 Comments »

Merck in the Middle of Statin Drug Soap Opera

November 9th, 2009. By AbiK

The latest flurry of statin drug-related news could substitute for your afternoon t.v. soap fix—except there’s a very real-life drama being played out. It’s full of intrigue and false promises. Who knew that the anti-cholesterol drug market could offer so much, and yet so little at the same time?

Here’s the topline history to get you up to speed—just in case you’ve missed the last couple of months’ news on drugs like Vytorin, Zetia and Lipitor…

Zetia + Simvastatin (aka Zocor) = Vytorin 

↓

Vytorin + Zetia = Class Action Settlement

↓

Zetia + Atorvastatin (aka Lipitor) = Refused by FDA = Bad News for Merck

↓

Vytorin + Arbiter 6 Study (due 11/16) = Expected Bad News for Merck 

↓

Niaspan + Arbiter 6 Study = Expected Good News for Abbott Labs 

So what’s the deal with this Arbiter 6 thing? It’s the clinical study that was conducted—and whose results are hotly anticipated at the American Heart Association (AHA) annual scientific meeting in Orlando on November 16th—to review the efficacy of cholesterol drugs Read the rest of this entry »

Tags: Arbiter 6, Merck, statins, Vytorin, Zetia
Posted in Drugs/Medical | 3 Comments »